The T cell immune response against SARS-CoV-2

P Moss - Nature immunology, 2022 - nature.com
The adaptive immune response is a major determinant of the clinical outcome after SARS-
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …

Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?

SJ Kent, DS Khoury, A Reynaldi, JA Juno… - Nature Reviews …, 2022 - nature.com
The rapid development of multiple vaccines providing strong protection from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a major achievement …

[HTML][HTML] Modeling transmission of SARS-CoV-2 omicron in China

J Cai, X Deng, J Yang, K Sun, H Liu, Z Chen, C Peng… - Nature medicine, 2022 - nature.com
Having adopted a dynamic zero-COVID strategy to respond to SARS-CoV-2 variants with
higher transmissibility since August 2021, China is now considering whether, and for how …

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

D Cromer, M Steain, A Reynaldi, TE Schlub… - The Lancet …, 2022 - thelancet.com
Summary Background Several SARS-CoV-2 variants of concern have been identified that
partly escape serum neutralisation elicited by current vaccines. Studies have also shown …

Evolution and neutralization escape of the SARS-CoV-2 BA. 2.86 subvariant

K Khan, G Lustig, C Römer, K Reedoy, Z Jule… - Nature …, 2023 - nature.com
Abstract Omicron BA. 2.86 subvariant differs from Omicron BA. 2 as well as recently
circulating variants by over 30 mutations in the spike protein alone. Here we report on the …

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

DS Khoury, D Cromer, A Reynaldi, TE Schlub… - Nature medicine, 2021 - nature.com
Predictive models of immune protection from COVID-19 are urgently needed to identify
correlates of protection to assist in the future deployment of vaccines. To address this, we …

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

M Shrotri, AMD Navaratnam, V Nguyen, T Byrne… - The Lancet, 2021 - thelancet.com
Vaccines based on the spike glycoprotein of SARS-CoV-2 are being rolled out globally to
control transmission and limit morbidity and mortality due to COVID-19. Current evidence …

[HTML][HTML] Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

KW Cohen, SL Linderman, Z Moodie, J Czartoski… - Cell Reports …, 2021 - cell.com
Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we
evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based …

BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory phenotype

G Guerrera, M Picozza, S D'Orso, R Placido… - Science …, 2021 - science.org
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
effective in preventing hospitalization from severe COVID-19. However, multiple reports of …

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

D Cromer, JA Juno, D Khoury, A Reynaldi… - Nature Reviews …, 2021 - nature.com
Immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
central to long-term control of the current pandemic. Despite our rapidly advancing …